FDA. Once on 'fast track,' avastin now derailed

Science. 2011 Jul 8;333(6039):143-4. doi: 10.1126/science.333.6039.143.
No abstract available

Publication types

  • News

MeSH terms

  • Angiogenesis Inhibitors / adverse effects
  • Angiogenesis Inhibitors / economics
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / economics
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / mortality
  • Drug Approval*
  • Drug Costs
  • Female
  • Humans
  • Survival Rate
  • United States
  • United States Food and Drug Administration*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab